Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101-Reference-Cited by-同舟云学术

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101

Published:2020-02-05 Issue:3 Volume:111 Page:907-923
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Uemura Motohide¹,Tomita Yoshihiko²,Miyake Hideaki³,Hatakeyama Shingo⁴^ORCID,Kanayama Hiro‐omi⁵,Numakura Kazuyuki⁶,Takagi Toshio⁷,Kato Tomoyuki⁸^ORCID,Eto Masatoshi⁹,Obara Wataru¹⁰^ORCID,Uemura Hirotsugu¹¹,Choueiri Toni K.¹²,Motzer Robert J.¹³,Fujii Yosuke¹⁴,Kamei Yoichi¹⁴,Umeyama Yoshiko¹⁴^ORCID,Pietro Alessandra¹⁵,Oya Mototsugu¹⁶

Affiliation:

1. Department of Urology Osaka University Graduate School of Medicine Osaka Japan

2. Department of Urology Department of Molecular Oncology Niigata University Graduate School of Medicine Niigata Japan

3. Department of Urology Hamamatsu University School of Medicine Hamamatsu Japan

4. Department of Urology Hirosaki University Graduate School of Medicine Hirosaki Japan

5. Department of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan

6. Department of Urology Akita University Graduate School of Medicine Akita Japan

7. Department of Urology Tokyo Women’s Medical University Tokyo Japan

8. Department of Urology Faculty of Medicine Yamagata University Yamagata Japan

9. Department of Urology Kyushu University Graduate School of Medical Sciences Fukuoka Japan

10. Department of Urology Iwate Medical University School of Medicine Morioka Japan

11. Department of Urology Faculty of Medicine Kindai University Osaka Japan

12. Lank Center for Genitourinary Oncology at Dana–Farber Cancer Institute Brigham and Women’s Hospital Boston Massachusetts USA

13. Memorial Sloan Kettering Cancer Center New York New York USA

14. Pfizer R&D Japan Tokyo Japan

15. Pfizer Lombardia Italy

16. Department of Urology Keio University School of Medicine Tokyo Japan

Funder

Pfizer

Merck KGaA

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14294

Reference35 articles.

1. Systemic Therapy for Metastatic Renal-Cell Carcinoma

2. Kidney cancer early detection diagnosis and staging.https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging.html. Accessed May 10 2019.

3. National Comprehensive Cancer Network. NCCN guidelines: Kidney cancer.2019.https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf. Accessed May 10 2019.

4. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

5. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer;International Journal of Urology;2024-02-06

2. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial;Journal for ImmunoTherapy of Cancer;2024-02

3. Real‐world outcomes of avelumab plus axitinib as first‐line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J‐DART);International Journal of Urology;2023-12-18

4. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017, based on A SEER Database;2023-08-17

5. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2023-05-04